Poseida Therapeutics, Inc. (PSTX)

NASDAQ: PSTX · IEX Real-Time Price · USD
1.97
-0.02 (-1.01%)
May 25, 2022 4:00 PM EDT - Market closed

Company Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.

The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).

It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers.

In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma.

Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates.

It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics, Inc.
Poseida Therapeutics Logo
CountryUnited States
Founded2014
IPO DateJul 10, 2020
IndustryBiotechnology
SectorHealth Care
Employees283
CEOEric Ostertag

Contact Details

Address:
9390 Towne Centre Drive
San Diego, California 92121
United States
Phone858 779 3100
Websiteposeida.com

Stock Details

Ticker SymbolPSTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$16.00
CIK Code1661460

Key Executives

NamePosition
Dr. Eric M. Ostertag M.D., Ph.D.Executive Chairman
Mark J. Gergen J.D.Chief Executive Officer and Director
Johanna M. Mylet CPAChief Financial Officer
Kerry D. IngallsChief Operating Officer
Kristin MartinChief People and Administrative Officer
Sarah ThailingSenior Director of Corporate Communications and IR
Harry J. Leonhardt Esq., J.D.General Counsel, Chief Compliance Officer and Corporate Secretary
Dr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell Therapies
Lisa PortaleSenior Vice President of Regulatory Affairs
Brent WarnerPresident of Gene Therapy

Latest SEC Filings

DateTypeTitle
May 18, 20223Initial statement of beneficial ownership of securities
May 18, 20228-KCurrent report
May 12, 202210-QQuarterly report [Sections 13 or 15(d)]
May 12, 20228-KCurrent report
Apr 27, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 27, 2022DEF 14AOther definitive proxy statements
Apr 25, 2022SC 13D/AGeneral statement of acquisition of beneficial ownership
Apr 7, 20228-KCurrent report
Mar 18, 20224Statement of changes in beneficial ownership of securities
Mar 10, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
View All SEC Filings